According to the literatures, nearly half of CTNNB1 mutant cases of endometrial carcinoma had only 5–10% of tumor cells with β-catenin nuclear localization, and the authors suggested that immunohistochemistry could be an initial screen, with CTNNB1 sequencing employed when nuclear localization of β-catenin is absent [9]. This evidence concerns the gene CTNNB1 and endometrial carcinoma.